Cannabidiol and neuroprotection: evidence from preclinical studies (2017)
- Authors:
- USP affiliated authors: HALLAK, JAIME EDUARDO CECILIO - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1016/B978-0-12-800756-3.00095-8
- Subjects: CANNABIS; ANTIOXIDANTES; DOENÇA DE ALZHEIMER; ANÓXIA; ISQUEMIA; FERRO; MODELOS ANIMAIS
- Language: Inglês
- Imprenta:
- Source:
- Título: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment
- Volume/Número/Paginação/Ano: 1143 p.
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SCHRÖDER, N. et al. Cannabidiol and neuroprotection: evidence from preclinical studies. Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. Tradução . London: Elsevier, 2017. p. 1143 . Disponível em: https://doi.org/10.1016/B978-0-12-800756-3.00095-8. Acesso em: 10 fev. 2026. -
APA
Schröder, N., Silva, V. K., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. de S. (2017). Cannabidiol and neuroprotection: evidence from preclinical studies. In Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment (p. 1143 ). London: Elsevier. doi:10.1016/B978-0-12-800756-3.00095-8 -
NLM
Schröder N, Silva VK, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol and neuroprotection: evidence from preclinical studies [Internet]. In: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. London: Elsevier; 2017. p. 1143 .[citado 2026 fev. 10 ] Available from: https://doi.org/10.1016/B978-0-12-800756-3.00095-8 -
Vancouver
Schröder N, Silva VK, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol and neuroprotection: evidence from preclinical studies [Internet]. In: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. London: Elsevier; 2017. p. 1143 .[citado 2026 fev. 10 ] Available from: https://doi.org/10.1016/B978-0-12-800756-3.00095-8 - Cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line MO3.13
- Marijuana, feijoada and the debate on drug legalization
- Cannabidiol for the treatment of psychosis in Parkinson's disease
- Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion
- Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy
Informações sobre o DOI: 10.1016/B978-0-12-800756-3.00095-8 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
